Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 10/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 10/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | JUN | P05412 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19152687 | 0.77 | PDE3B (0.46) | PDE3BPDE3ADAOGRM1 | |
| SCHEMBL19131092 | 0.73 | PDE3B (0.41) | PDE3BPDE3A | |
| SCHEMBL18238489 | 0.73 | PDE3B (0.47) | PDE3BPDE3A | |
| SCHEMBL18168235 | 0.67 | TYRO3 (1.00) | TYRO3DYRK1BPDE3BPDE3AKDM4E | |
| SCHEMBL8663220 | 0.67 | RPS6KA3 (0.32) | TYRO3DYRK1B | |
| SCHEMBL29502006 | 0.67 | TYRO3 (1.00) | TYRO3DYRK1BPDE3BPDE3AKDM4E | |
| SCHEMBL9035348 | 0.67 | TYRO3 (0.72) | TYRO3DYRK1BJUNNFKB1NFKB2 | |
| SCHEMBL25272619 | 0.65 | TYRO3 (0.50) | TYRO3DYRK1BJUNNFKB1NFKB2 | |
| SCHEMBL18128044 | 0.65 | TYRO3 (0.50) | TYRO3DYRK1BPDE3BPDE3AJUN | |
| SCHEMBL12232628 | 0.65 | PDE3B (0.54) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | USP1, USP2, USP3 | TYRO3 4644/4885DYRK1B 3057/4885PDE3B 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.